Radius Health partners with Novartis to evaluate RAD1901 combination regimens in advanced breast can
Radius Health has entered into a worldwide clinical collaboration with Novartis Pharmaceuticals to evaluate the safety and efficacy of combining investigational agent RAD1901, a novel oral selective estrogen receptor degrader (SERD), with investigational agent LEE011 (ribociclib), a cyclin-dependent kinase (CDK) 4/6 inhibitor.
Click on this link for more information.
